Journal of diabetes & metabolism最新文献

{"title":"The Quality of Life in Patients with Diabetic Foot Ulcers","authors":"M. Arshad, S. Arshad, S. Arshad, Hina Abbas","doi":"10.35248/2155-6156.20.11.e101","DOIUrl":"https://doi.org/10.35248/2155-6156.20.11.e101","url":null,"abstract":"Diabetes mellitus is one of the commonest chronic diseases, resulting in a lot of complications including a diabetic foot ulcer. Diabetic foot ulcers (DFU) including the risk to progress to amputation, also deteriorate the quality of life of the patients and their care givers. Diabetic foot ulcers not only affect the physical health-related quality of life (HRQoL) of patients but the social, psychological and economic aspects of the patient’s life are also affected. Research studies have shown that factors such as female gender, obesity, presence of Peripheral Vascular Disease and stressful life events further decrease the quality of life in patients with diabetic foot ulcers. This editorial advocates that diabetic foot ulcers being a huge burden on the healthcare system also deteriorate the quality of life of patients.","PeriodicalId":15597,"journal":{"name":"Journal of diabetes & metabolism","volume":"64 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88947697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of Oral Administration of Lauric Acid Supplement on Fasting Blood Glucose Level and Pancreatic Histomorphological Studies in High Fat Diet/Streptozotocin-Induced Type 2 Diabetic Male Wistar Rats","authors":"E. Alex, A. Dubo, D. Ejiogu, KW Iyomo, KV Jerome, N. Aisha, AO Daikwo, J. Yahaya, RO Osiyemi, J. Yaro","doi":"10.35248/2155-6156.20.11.849","DOIUrl":"https://doi.org/10.35248/2155-6156.20.11.849","url":null,"abstract":"Background: Diabetes mellitus is the most common serious metabolic disease in human with a hall-mark of an elevated blood glucose concentration caused by a number of biochemical and physiological alterations Aim: The aim of the study was to evaluate the effect oral administration of lauric acid supplement on fasting blood glucose level and pancreatic histomorphological studies in high fat diet/streptozotocin (STZ)-induced type 2 diabetic male Wistar rats. Study Design: Thirty-five apparently healthy male Wistar rats of 6-8 weeks, weighing between 70 g-90 g were grouped into seven groups of five animals each (n=5) and treated for a period of twenty-one days (21) with graded doses of lauric acid supplement after validation of diabetes. Group 1 and 3 were fed with normal rat feed while group 2, 4, 5, 6, 7 were fed with high fat diet for eight weeks after which low dose STZ was given to same groups. Methodology: Group 1: (Normal control), Group 2: (Diabetic control untreated), Groups 3: (Normoglycemic) received 125 mg/kg Lauric acid, Group 4, 5 and 6 were administered 125, 250 and 500 mg/kg body weight of lauric acid, Group 7: (Standard control) received metformin 100 mg/kg. Blood glucose level was determined at weekly intervals using glucose test strips and digital glucometer (Accu-Chek Advantage, Roche Diagnostic, Germany). At the end of twenty-one (21) days, rats were anaesthetized using ketamine and xylazine at 75 and 25 (mg/kg) respectively. The Pancreatic tissues were excised and subjected to routine histological investigation for histo-pathological changes. Result: The results showed that lauric acid at all doses significantly (P<0.05) decreased the fasting blood glucose level from (32.45 ± 0.54, 28.85 ± 1.81, 28.85 ± 2.52 mmo/L) to (7.9 ± 1.07, 5.27 ± 0.39 and 4.45 ± 0.48 mmol/L) after three weeks of treatment. And also, Subsequent histomorphological evaluation also showed necrosis and vacuolization of islet β-cells to be reasonably reduced in the diabetic treated rats Conclusion: This study has been able to demonstrate the Antidiabetic potential of graded doses of lauric acid supplementations for 21 days of administration and it has found out that it possesses strong Antihyperglycemic potencies and induced β-cell regeneration in high fat diet/streptozotocin induced type 2 diabetic rat models.","PeriodicalId":15597,"journal":{"name":"Journal of diabetes & metabolism","volume":"29 1","pages":"1-7"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87180832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Proof of Concept Study to Evaluate the Impact of an Established Telehealth Mood Monitoring System on Mood in Individuals with Type 2 Diabetes when Initiating an Injectable Therapy","authors":"H. Price, O. Agbaje, J. Price, G. Goodwin, J. Geddes, R. Holman","doi":"10.35248/2155-6156.20.11.857","DOIUrl":"https://doi.org/10.35248/2155-6156.20.11.857","url":null,"abstract":"Background: We aimed to determine the feasibility of using an established telehealth system to monitor potential mood changes in individuals with type 2 diabetes when commencing an injectable glucose-lowering therapy. Methods: Individuals with type 2 diabetes commencing an injectable therapy as part of their routine clinical care when not achieving glycemic control on oral antidiabetic therapy, or when instituted as part of a randomized clinical trial, were asked to self monitor their mood for six months. Participants were asked to complete the Quick Inventory of Depressive Symptoms–Self Report (QIDS-SR) weekly and the Diabetes Distress Scale (DDS17) monthly. Results: Seven participants were recruited who all initiated an injectable therapy and were followed up for median 33 (27–37) weeks. Median (IQR) proportions of returned QIDS-SR and DDS17 questionnaires were 100% (86%–100%) and 100% (100%–100%) respectively, with completeness 88% (80%–100%) and 100% (100%–100%). DDS17 scores increased (worsened) during the first month after injectable therapy initiation, followed by a gradual decline in QIDS-SR scores and stabilizing DDS17 responses. Conclusion: We show that an online self-management system can be used to monitor mood remotely in type 2 diabetes population, and could provide additional metrics to help inform diabetes management.","PeriodicalId":15597,"journal":{"name":"Journal of diabetes & metabolism","volume":"3 1","pages":"1-5"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86909130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of High-Protein High-Fibre Supplement on Glycaemic Control in Overweight and Obese Indian Adults with Type 2 Diabetes Mellitus: A 24-Week, Randomized, Controlled Trial","authors":"R. Bhoite, Anitha Ch, rasekaran, Shivani Aacharya, A. Mane, S. Mehta, R. Kale, G. Nagamuthu, Sasikala Selvaraj, G. Rajagopal, Sudha Vasudevan, A. Mohan, R. Unnikrishnan, Kamala Krishnaswamy, M. Viswanathan","doi":"10.35248/2155-6156.20.11.846","DOIUrl":"https://doi.org/10.35248/2155-6156.20.11.846","url":null,"abstract":"Background: Foods rich in protein, dietary fibre and low in glycaemic index could potentially improve glycaemic control and help in management of type 2 diabetes mellitus (T2DM) in overweight/obese participants. In this study, the effect of high-protein high-fibre (HPHF) nutritional supplement in addition to standard medical care for glycaemic control was evaluated. Methods: In this open-label, parallel-arm, randomised study, 100 overweight/obese participants with T2DM (aged 30-65 years) were randomised (1:1) to either intervention group (25 g HPHF nutritional supplement [twice daily]+standard care of T2DM) or a control group (standard care of T2DM), for 6 months. Primary endpoint included change from baseline in 24â�?�?hour glycaemic response at weeks 12 and 24. Results: Of 320 participants screened, 100 participants were randomised to either the intervention group (n=50) or the control group (n=50). In the intervention group; the mean (SE) daily incremental area under curve (IAUC) from baseline to week 24 was significantly lower â�?�?23.0 mg-15min/dL (57.2) compared to control group 168.0 mg-15min/ dL (39.0), p=0.008. The intervention group showed significant reduction in glycosylated haemoglobin (HbA1c) (p=0.03) and fasting blood sugar (p=0.01) level at the end of week 24 compared to the control group. Conclusions: Twice-daily consumption of HPHF nutritional supplement (25 g each) significantly improved glycaemic control, reduced the average 24-hour glycaemic response and postprandial glucose spikes. Inclusion of HPHF supplement would be a useful effective aid to glycaemic control in overweight/obese participants with T2DM.","PeriodicalId":15597,"journal":{"name":"Journal of diabetes & metabolism","volume":"50 1","pages":"1-8"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84992532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Define-HF and Emperial Trials: Lessons Learned","authors":"S. Ghosal","doi":"10.35248/2155-6156.20.11.848","DOIUrl":"https://doi.org/10.35248/2155-6156.20.11.848","url":null,"abstract":"Sodium Glucose co-transporter inhibitors (SGLT-2i) have firmly established their position in the management of type 2 diabetes mellitus (T2DM) and have also expanded their indication for use. There were different outcomes benefits with the three SGLT-2i, resulting from differences in patient population studied, primary end-points chosen and statistical testing hierarchy. Although the outcome benefits complemented each other, the subtle differences were blown out of proportion by interested lobbies, eyeing a larger pie of the market share. The corporate war intensified with the publication and top-line results of 2 two recent symptom-based trials in patients with heart failure (DEFINEHF & EMPERIAL). Once again, the differences were subtle and there were more similarities than differences. Diuretics provide the desired symptom relief whereas SGLT-2i are associated with hard end-point outcome benefits. In view of the profound benefits associated with the use of SGLT-2i two additional categories of studies were launched. The first explored the area of symptomatic relief and the second concentrated on the mechanistic benefits. This review looks in depth at the different types of trials conducted with SGLT-2i and their similarities which is supported by all the recently published guidelines.","PeriodicalId":15597,"journal":{"name":"Journal of diabetes & metabolism","volume":"110 1","pages":"1-5"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87658769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial-Journal of Diabetes and Metabolism","authors":"P. Karunasree","doi":"10.35248/2155-6156.20.11.E102","DOIUrl":"https://doi.org/10.35248/2155-6156.20.11.E102","url":null,"abstract":"LONGDOM Journal of Diabetes & Metabolism has been started in the year 2010 and it released its first volume in the same year. Till now, the journal has released 10 volumes by the end of 2019 and is successfully running its 11th Volume.","PeriodicalId":15597,"journal":{"name":"Journal of diabetes & metabolism","volume":"15 1","pages":"1-2"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73071778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-diabetic, Haematinic and Anti-cholesterolmic Effects of Wheat (Triticum aestivum Linn.) Grass Juice Metabolites to Cure Alloxan Monohydrate induced type-1 Diabetes in Albino Rats","authors":"Sanjeev Kumar, K. Shachi, N. K. Prasad, N. Dubey, U. Dubey","doi":"10.35248/2155-6156.20.11.842","DOIUrl":"https://doi.org/10.35248/2155-6156.20.11.842","url":null,"abstract":"Introduction: From time immemorial therapeutic potential of Triticum aestivum grass is known. In present study an effort has been made to assess the hypoglycemic, anti-cholesterolmic and haematinic activity of Triticum aestivum grass juice in alloxan monohydrate induced experimental animal model. Materials and methods: Rats were acclimatized for 7 days in lab temperature. All animals were given standard water and pellet diet. Diabetes was induced in rats with the help of alloxan monohydrate (120 mg/kg body weight). After alloxan monohydrate injection rats were separated and treatment started with Triticum aestivum grass juice and insulin. Blood glucose level monitored with the help of glucometer. Results and discussion: A marked rise in fasting blood glucose as well as serum cholesterol level was observed in diabetic control rats when compared to normal control rats. Anti- hyperglycemic, anti-cholesterolmic and haematinic activity observed in Triticum aestivum grass juice administered rats on 7th, 14th, 21st and 28th days post treatment. Antihyperglycemic and anti-cholesterol mic activity was found less effective than that of insulin treatment group. Conclusion: It is hope that present investigation will be helpful in establishing a scientific basis for anti-diabetic, haematinic and anti- cholesterolmic effects in experimental animal models. The results are (<0.05) statistically significant.","PeriodicalId":15597,"journal":{"name":"Journal of diabetes & metabolism","volume":"4 1","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87434157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Teneligliptin as Add on Therapy in Indian Type 2 Diabetes Mellitus Patients having Dyslipidemia","authors":"M. ParmarVinendra, S. GoswamiSunita","doi":"10.35248/2155-6156.20.11.844","DOIUrl":"https://doi.org/10.35248/2155-6156.20.11.844","url":null,"abstract":"Objectives: The purpose of this study was to investigate the efficacy and safety of teneligliptin, a completely unique and highly selective DPP-4 inhibitor in type 2 diabetes mellitus (T2DM) patients having dyslipidemia who are inadequately controlled by relevant conventional therapy in India. Methods: Study protocol was approved by Institutional Ethics Committee. Diabetic patients having dyslipidemia (male/female) were randomized to receive treatments in two groups, namely conventional therapy [treatment (A)] and add on teneligliptin 20 mg with conventional therapy [treatment (B)] for 24 weeks. Predesigned case report form (CRF) was used to collect information from the prescribing physicians regarding the efficacy and safety of teneligliptin. Efficacy variables included change in serum glycaemic, lipid, and cytokines (IL-6, TNF-α and adiponectin) levels from baseline to week 24. Treatment-emergent adverse events (TEAEs) were also assessed. Results: A complete of 120 T2DM patient having dyslipidemia were analysed using graph pad prism. Teneligliptin, as add on therapy to conventional therapy significantly reduced serum lipid profile (TC, TG, and LDL) as well as glycaemic parameters (HbA1c, FBG, and PPBG) along with significant rise in serum adiponectin levels as compared to conventional therapy. Conclusion: Add- on therapy with teneligliptin was found better option over convetional therapy in term of significantly reduced glycemic as well as lipid profile. Further, it was found safe and well tolerated in T2DM patients having dyslipidemia.","PeriodicalId":15597,"journal":{"name":"Journal of diabetes & metabolism","volume":"15 1","pages":"1-8"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89352859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Empagliflozin Ameliorating Effect of on Plasma Triglyceride: An Association with Endothelial Function Recovery in Diabetic Patients with Coronary Artery Disease","authors":"T. Sawada, K. Uzu, Naoko Hashimoto, T. Onishi, Tomohumi Takaya, A. Shimane, Y. Taniguchi, Y. Yasaka, Takeshi Ohara, H. Kawai","doi":"10.35248/2155-6156.19.10.827","DOIUrl":"https://doi.org/10.35248/2155-6156.19.10.827","url":null,"abstract":"Introduction: The mechanisms behind the cardiovascular benefits of Sodium-Glucose Co-Transporter 2 (SGLT2) inhibitors have not been fully clarified. We aimed to identify potential mechanisms underlying the favorable effects of SGLT2 inhibitors on cardiovascular events. \u0000 \u0000Methods: The 50 diabetic patients with established Coronary Artery Disease (CAD) included in this study analysis were administered 10 mg/day of empagliflozin. Cookie meal testing (carbohydrates: 75 g, fat: 28.5 g), endothelial function testing using Flow-Mediated Dilatation (FMD), and body composition evaluation were performed before and after 6 months treatments. Evaluation of changes in % FMD between treatment periods, and its association with metabolic biomarkers were evaluated. \u0000 \u0000Results: After the 6 month treatment, body weight and body fat percentage decreased significantly, while body muscle percentage increased significantly. HbA1C level and fasting and postprandial plasma glucose levels were significantly decreased by treatment. Postprandial insulin secretion was also significantly suppressed and insulin resistance index was significantly decreased. Furthermore, fasting and postprandial triglyceride levels decreased significantly while total ketone body increased significantly after the 6 months treatment. While plasma brain natriuretic peptide level was not changed, C-reactive protein was decreased, and FMD was significantly improved after the 6 months treatment. Multiple regression analysis showed the strongest predictive factor of FMD improvement to be change in fasting and postprandial plasma triglyceride levels. \u0000 \u0000Conclusion: SGLT2 inhibitors improved multiple metabolic parameters. Of these, reduction in plasma triglyceride was strongly associated with endothelial function recovery in diabetic patients with CAD, and this reduction may be related to the cardiovascular benefit of SGLT2 inhibitors.","PeriodicalId":15597,"journal":{"name":"Journal of diabetes & metabolism","volume":"112 8","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91485083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Helicobacter pylori in patients undergoing laparoscopic sleeve gastrectomy. Should we really care?","authors":"Brianna Twomey","doi":"10.4172/2155-6156-c1-103","DOIUrl":"https://doi.org/10.4172/2155-6156-c1-103","url":null,"abstract":"","PeriodicalId":15597,"journal":{"name":"Journal of diabetes & metabolism","volume":"37 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85014850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}